SequelSEC

RESMED INC RMD

Surgical & Medical Instruments & Apparatus · CIK 0000943819 · Fiscal year ends 0630

Revenue
$5.65B
Fiscal year ended 2026-06-30
Operating income
$1.89B
Fiscal year ended 2026-06-30
Free cash flow
$1.65B
Fiscal year ended 2026-06-30

RESMED INC (RMD) reported revenue of $5.65B and net income of $1.52B for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from RESMED INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

RESMED INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Revenue$5.65B$5.15B$4.69B$4.22B$3.58B$3.20B$2.96B$2.61B$2.34B$2.07B
Cost of revenue$2.20B$2.09B$2.03B$1.87B$1.55B$1.36B$1.24B$1.11B$1.01B$864.99M
Gross profit$3.45B$3.05B$2.66B$2.36B$2.02B$1.84B$1.72B$1.49B$1.33B$1.20B
Operating income$1.89B$1.69B$1.32B$1.13B$1.00B$903.68M$809.66M$579.26M$541.83M$425.80M
Net income$1.52B$1.40B$1.02B$897.56M$779.44M$474.50M$621.67M$404.59M$315.59M$342.28M
Research & development$378.28M$331.28M$307.52M$287.64M$253.58M$225.28M$201.95M$180.65M$155.15M$144.47M
Weighted-average diluted sharesshares 146.05Mshares 147.34Mshares 147.55Mshares 147.46Mshares 147.04Mshares 146.45Mshares 145.65Mshares 144.48Mshares 143.99Mshares 142.45M
Pretax income$1.92B$1.68B$1.26B$1.10B$960.48M$883.66M$733.09M$518.85M$521.31M$418.74M
Income tax expense$396.12M$276.84M$243.85M$204.11M$181.05M$409.16M$111.41M$114.26M$205.72M$76.46M
Diluted EPS$10.43$9.51$6.92$6.09$5.30$3.24$4.27$2.80$2.19$2.40
Selling, general & administrative$1.12B$993.05M$917.14M$874.00M$737.51M$670.39M$676.69M$645.01M$600.37M$553.97M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

RESMED INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Cash & equivalents$1.47B$1.21B$238.36M$227.89M$273.71M$295.28M$463.16M$147.13M$188.70M$821.94M
Total assets$8.97B$8.17B$6.87B$6.75B$5.10B$4.73B$4.59B$4.11B$3.06B$3.47B
Current assets$4.32B$3.51B$2.36B$2.37B$1.93B$1.57B$1.52B$1.15B$1.07B$1.64B
Total liabilities$2.38B$2.21B$2.01B$2.62B$1.74B$1.84B$2.09B$2.04B$1.00B$1.51B
Current liabilities$1.40B$1.02B$910.66M$758.53M$689.30M$911.77M$602.76M$555.99M$511.25M$360.13M
Total equity incl. NCI$6.59B$5.97B$4.86B$4.13B$3.36B$2.89B$2.50B$2.07B$2.06B$1.96B
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$945.80M$927.71M$822.25M$998.01M$743.91M$457.03M$416.92M$349.64M$268.70M$268.32M
Accounts receivable$1.04B$939.49M$837.28M$704.91M$575.95M$614.29M$474.64M$528.48M$483.68M$450.53M
Goodwill$2.91B$3.05B$2.84B$2.77B$1.94B$1.93B$1.89B$1.86B$1.07B$1.06B
Long-term debt$399.42M$658.39M$697.31M$1.43B$765.32M$643.35M$1.16B$1.26B$269.99M$1.08B
Accounts payable$308.92M$278.16M$237.73M$150.76M$159.24M$138.01M$135.79M$115.72M$92.72M$92.76M

Cash flow

RESMED INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Operating cash flow$1.81B$1.75B$1.40B$693.30M$351.15M$736.72M$802.26M$459.05M$505.03M$414.05M
Capital expenditures$156.28M$89.86M$99.46M$119.67M$134.84M$102.71M$95.33M$68.71M$62.58M$62.22M
Investing cash flow-$545.20M-$200.04M-$269.78M-$1.16B-$229.92M-$158.46M-$179.86M-$1.08B-$101.82M-$81.89M
Financing cash flow-$1.01B-$606.25M-$1.12B$422.87M-$128.36M-$764.63M-$317.29M$580.64M-$1.03B-$262.87M
Net change in cash$259.78M$971.09M$10.47M-$45.82M-$21.57M-$167.88M$316.03M-$41.57M-$633.23M$90.50M
Stock-based compensation$104.35M$91.66M$80.18M$71.14M$65.26M$63.93M$57.56M$52.07M$48.41M$45.92M
Common dividends paid$349.66M$310.88M$282.32M$258.28M$245.34M$226.71M$225.09M$211.71M$199.50M$186.35M
Common share repurchases$700.04M$300.02M$150.01M$0$0UnavailableUnavailable$22.84M$53.80MUnavailable
Depreciation & amortization$201.34M$198.47M$176.87M$165.16M$159.61M$156.76M$154.85M$150.80M$119.96M$112.16M

Derived

RESMED INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-30
Free cash flow$1.65B$1.66B$1.30B$573.63M$216.31M$634.01M$706.92M$390.34M$442.44M$351.83M
Gross margin61.1%59.4%56.7%55.8%56.6%57.5%58.1%57.3%57.0%58.1%
Operating margin33.4%32.7%28.2%26.8%28.0%28.3%27.4%22.2%23.2%20.6%
FCF margin29.2%32.3%27.8%13.6%6.0%19.8%23.9%15.0%18.9%17.0%
SBC / revenue1.8%1.8%1.7%1.7%1.8%2.0%1.9%2.0%2.1%2.2%
Current ratio3.10x3.44x2.59x3.12x2.80x1.73x2.53x2.06x2.08x4.57x
Revenue YoY growth9.9%9.8%10.9%18.0%11.9%8.1%13.4%11.4%13.2%Unavailable
Net margin26.9%27.2%21.8%21.3%21.8%14.8%21.0%15.5%13.5%16.6%
R&D / revenue6.7%6.4%6.6%6.8%7.1%7.0%6.8%6.9%6.6%7.0%
CapEx / revenue2.8%1.7%2.1%2.8%3.8%3.2%3.2%2.6%2.7%3.0%
Long-term debt / equity0.06x0.11xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate20.6%16.5%19.3%18.5%18.8%46.3%15.2%22.0%39.5%18.3%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-Q · Filed 2026-01-30View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-K · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-04-24View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.